129Xe Hyperpolarized

Phase 2

HeartSciences Inc. (HSCSW)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

HSCSWPhase 2

129Xe Hyperpolarized Phase 2 Est. Readout

129Xe Hyperpolarized• Pulmonary Arterial Hypertension20

Jan 2027~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in Pulmonary Arterial Hypertension

KROSDose A KER-012

Phase 2

View Full Landscape

Drug Information

Target Indication

Pulmonary Arterial Hypertension

Clinical Trial

NCT06104228

Last updated: 9/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

HSCSW

HeartSciences Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]Phase 3

Iron-deficiency

Sacubitril-Valsartan 49 Mg-51 Mg Oral TabletPhase 3

Obesity

Mono-Therapy with SildenafilPhase 3

Pediatric Pulmonary Hypertension

Convalescent PlasmaPhase 3

Covid19

FosinoprilPhase 3

Microalbuminuria

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts